TOMI Expands SteraMist iHP into India’s Booming Pharmaceutical Market
Event summary
- TOMI partners with STS Technocrat (India) to distribute SteraMist iHP in India’s pharmaceutical sector.
- STS Technocrat signed a major pharmaceutical customer, creating a reference site for future deals.
- India’s pharmaceutical market grew 11% in 2026 and is projected to reach $174.67B by 2034 (CAGR 10.98%).
- STS Technocrat will also manufacture a turnkey SteraMist iHP enclosure for local production.
The big picture
TOMI’s expansion into India’s fast-growing pharmaceutical market leverages local partnerships to address rising demand for low-downtime decontamination. The $75.89B market (2026) is projected to nearly triple by 2034, driven by production scaling and regulatory compliance. Success hinges on replicating U.S. adoption patterns through strategic referrals and localized manufacturing.
What we're watching
- Market Adoption
- Whether TOMI can replicate U.S. referral-driven growth in India’s pharmaceutical sector.
- Execution Risk
- The pace at which STS Technocrat scales SteraMist iHP production and distribution.
- Regulatory Compliance
- How India’s alignment with global GMP standards will impact demand for validated decontamination solutions.
Related topics
